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Abstract 
Purpose  This study aimed to evaluate serum cytochrome c (cyto-c) levels 
as a novel role of tumor marker in patients with operable malignant tumors.  
Methods  Serum cyto-c levels and lactate dehydrogenase (LD) activity were 
measured in a total of 257 cases (232 malignant and 25 benign). To identify the 
relationship between serum cyto-c and current tumor markers, 6 variables, such as 
gender, age, invasion, lymph node metastasis, distant metastasis, and LD, were 
analyzed by uni- and multivariate regression analysis methods. The test performance 
of serum cyto-c for the prediction of malignant behavior was evaluated by receiver 
operating characteristic (ROC) curves.  
Results The serum cyto-c level was significantly higher in patients with malignant 
tumors than patients with benign tumors (20.6 ng/mL versus 15.5 ng/mL; P = 0.017, 
Mann-Whitney U test). No difference in the levels among subtypes of cancer was found, 
indicating that the change in serum cyto-c levels reflect cancer individually and not 
specific subtypes of cancer.  The survival in patients with serum cyto-c levels over 40 
ng/mL was poor (Kaplan-Meier test, p < 0.0001, Hazard ratio 16.76, 95% confidential 
interval 4.45-63.04). Multiple linear regression analyses disclosed the close association 
of serum cyto-c levels with invasion (P = 0.0004), metastasis (P = 0.0262) except for 
regional lymph node metastasis, and activity of serum LD (P < 0.0001), all of which are  
well known to represent malignant behavior. Conversely, the measurement of serum 
cyto-c was verified to have excellent diagnostic accuracy of 0.802 and 0.781 for the 
detection of invasion and metastasis (the area under curves of the constructed ROCs).  
Conclusion Serum cyto-c is a potent tumor marker as a predictor for 
malignant potential in cancers. 
 
Keywords Cytochrome c・Prediction・Tumor marker・Metastatic potential 
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 Introduction 
Circulating tumor markers are used to define a particular disease entity in clinical 
settings for diagnosis, staging, and monitoring. Tumor markers are usually proteins 
released from dying tumor cells or elaborated by neoplastic cells. There are two 
subcategories of the proteins, specific and non-specific. Tumor specific proteins are 
expressed only in tumor cells, such as chimeric fusion proteins associated with 
malignant processes, leading to the development of a malignant clone. These protein 
markers are very useful for the detection and diagnosis of specific malignant tumors. 
On the other hand, non-specific proteins or markers related to malignant cells are 
onco-fetal or carcinogenic antigens, such as carcinoembryonic antigen (CEA), 
alphafetoprotein, prostate specific antigen (PSA), CA15.3, and CA19-9, all of which are 
still useful for screening, monitoring, staging, and prognosis, although their diagnostic 
specificity is not especially high. Recently, besides these classical tumor markers, cell 
specific proteins over-expressed in malignant cells have become available because 
differentiated wild-typed cells normally express these markers at a subtle and constant 
level but the corresponding tumor cells express it at a high level. For example, soluble 
IL-2 receptors, VEGF, and so on, are closely associated with the cell cycle, apoptosis, 
signal transduction, angiogenesis, and invasion (Holdenrieder and Stieber 2004). 
Cancer is characterized by cell division and cell death. However, there are no 
appropriate cell death markers available for use in a clinical setting, although the 
activity of serum LD is employed as a universal death marker. Recently, cytokeratine 18, 
nucleosomes, fragmented DNA, and cyto-c in serum have been discussed as novel 
markers for the evaluation of apoptotic death (Beachy and Repasky 2008).  
It has been reported that cytochrome c (cyto-c) is released into the culture medium 
after activation of the intrinsic apoptotic caspase pathway in vitro and some patients 
with hematological malignancies have high levels of serum cyto-c. Barczyk et al. (2005) 
also showed that the change in serum cyto-c levels is useful for monitoring of 
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therapeutic responsiveness and prognostic prediction upto 3 years later. Therefore, this 
study addressed the potential use of serum cyto-c as a surrogate marker alternative to 
pathological assessment in patients with operable malignant tumors.   
 
 Patients and Methods 
Serum specimens 
Serum specimens and clinical information were collected under the regulations of the 
Ethical Board criteria defined by the Japanese Association of Laboratory Medicine. A 
total of 257 patients (232 malignant and 25 benign) was enrolled in this study. Serum 
cyto-c and LD were measured in all cases, and CEA and CA-19-9 were measured in 28 
cases of gastric cancer and in 37 cases of colorectal cancer (CRC). All sera were 
stored at -40℃ until measurement. Pretreatment serum cyto-c levels were measured 
using serum samples collected from individuals diagnosed as having lung, 
gastro-intestinal, colorectal, breast, uro-genital, ovaro-uterine cancers, and benign 
tumors. Benign tumors consisted of tubular adenoma of the colon, serous cystadenoma, 
thymoma, severe dysplasia of the uterus, moderate dysplasia of the urinary bladder, 
and prostatic hyperplasia. Almost all patients were operable status but 9 were 
inoperable. No patient was treated preoperatively with either chemotherapy or radiation 
therapy. The median follow-up period was 6 months, ranging from 1 to 19 months. Of 
249 cases available for histological examination, invasion and metastasis were 
evaluated according to the tumor-node-metastasis (TNM) staging system. The 
presence of distant metastasis was detected by image analysis.  
 
Cytochrome c quantification 
Human cyto-c was quantified using an in-house electrochemiluminescence 
immunoassay method. Twenty µL of serum sample diluted 1:11 with 200 µL of reaction 
buffer was incubated with 3 x 107 micro magnetic beads (Invitrogen, Carlsbad, USA) 
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coated with anti-cyto-c monoclonal antibody for 9 min at 30°C. After the beads were 
washed two times with washing buffer, 200 µL of another anti-cyto-c monoclonal 
antibody coupled with ruthenium(II) Tris (bipyridyl)-N-hydroxysuccinimide ester 
[Ru(bpy)32+] (BioVeris, Gaithersburg, USA) was added to the beads and incubated for 
9 min at 30°C. After the beads were washed three times with washing buffer, the beads 
were conducted into the electrode and the photons (wavelength, 620 nm) emitted from 
the Ru(bpy) 32+ coupled to the anti-cyto-c monoclonal antibody were counted with a 
photo-multiplier tube. To quantify the cyto-c present in the serum sample, purified 
human cyto-c (R & D Systems, Minneapolis, USA) as a standard antigen was assayed 
in parallel. The above ECLIA procedures were carried out with an automatic ECLIA 
analyzer (Picolumi 8220; Sanko Junyaku, Tokyo, Japan). Then, serum LD was 
measured by the International Federation of Clinical Chemistry (IFCC)-recommended 
method. CEA and CA19-9 were measured based on chemiluminescence enzyme 
immunoassay technology using commercially available kits, 
LUMIPULUSEpicorna-CEA and PULUSE-picorna-CA-19-9 (SRL Inc, Tokyo, Japan) 
 
Statistical analysis 
Differences in the distribution of cyto-c with clinical and pathological feautures were 
used for univariate and multivariate analysis. Mann-Whitney U test and Kruskal-Wallis 
H test were used for univariate analysis. To compare the abilities of tumor markers to 
distinguish patients with r/o metastasis and invasion, receiver operating characteristic 
(ROC) curves were constructured. In addition, areas under the ROC curves (AUCs) 
with 95% confidence intervals (CI) were calculated for cyto-c, LD, CEA, and CA19-9. 
The optimal cut-off value for cyto-c was determined by Youden’s index. Survival rates 
were calculated by the Kaplan-Meier method, and were compared with log-rank test. 
For all analyses, a two-tailed P value of < 0.05 was considered statistically significant. 
Statistical analyses were performed using “StatFlex Ver.5.0” software. 
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Results 
 Distribution of serum cyto-c levels 
The basic patient characteristics of enrolled patients are summarized in Table 1. Of a 
total of 257 cases, the median cyto-c levels were 20.6 ng/mL (IQR;16.2-29.2, range 
7.2-629.3) in 232 patients with malignant tumors and and 15.5 ng/mL (IQR; 11.8-19.4, 
range 8.5-52.5)  in 25 patients with benign tumors, respectively (P = 0.002, 
Mann-Whitney U test). Individual data were displayed as plots of the median and 5th, 
25th, 75th, and 95th percentiles of the preoperative cyto-c levels in each group, as shown 
in Figure 1. No difference in each cyto-c level was observed among the 10 subtypes of 
malignant tumor (P = 0.362, Kruskal-Wallis H test), revealing that serum cyto-c was not 
specific for tumor types. Diagnostic sensitivity and specificity to discriminate malignant 
from benign tumors were 55.6% and 76.0% when the cut-off was 19.4 ng/mL based on 
the maximization of Youden’s index. 
Twelve patients died during this study period, and 6 of them had cyto-c levels over 
100ng/mL, which indicates the potent prognostic value of cyto-c. Survival curves were 
compared among patient groups with different serum cyto-c levels, < 40, 40–99, and > 
100 ng/mL. The Kaplan-Meier curve revealed that survival was significantly poorer in 
patients with the serum cyto-c level over 40 ng/mL (p < 0.0001, Hazard ratio 16.76, 
(95% confidential interval 4.45-63.04) (Figure 2) 
 
Performance of cyto-c in predicting the presence of invasion and metastasis 
The results are shown in Table 2. The cyto-c level was statistically associated with 
invasion (P < 0.0001), metastasis (P < 0.001), and high LD activity (p < 0.0001, 
Mann-Whitney U test). Multiple linear regression analysis also showed significant 
association of the elevation of serum cyto-c levels with invasion (P = 0.0004), 
metastasis (P = 0.0262), and LD (P < 0.0001). The performance characteristics of 
serum cyto-c as a laboratory test were analyzed using the ROC curve for two predictive 
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factors (metastasis and invasion) in comparison with LD, CEA, and CA19-9. The 
preoperative ROC-AUC of cyto-c was higher than those of the other markers, as shown 
in Figure 3 (AUC for metastasis = 0.781 (95% CI = 0.711-0.852) and AUC for invasion = 
0.802 (95%CI = 0.730-0.873)). Based on the maximization of Youden’s index, the 
optimal cut-off values for cyto-c in preoperative patients with cancer were 22.7 ng/mL 
(sensitivity, 81.6%; specificity, 68.9%) for metastasis, and 22.3 ng/mL (sensitivity, 
86.5%; specificity, 66.9%) for invasion. 
 
   Validation of cyto-c for subtypes of tumor 
To examine the usefulness of cyto-c in respective cancer types, the same analyses 
were conducted for 31 patients with gastric cancer and 44 patients with CRC. In gastric 
cancers, as shown in Table 3, cyto-c at the preoperative stage was significantly 
associated with advanced stage (P < 0.001), the presence of distance metastasis (P = 
0.009), and progression (P = 0.031), CEA, CA19-9 and LD did not show statistically 
significant associations. Moreover, the ROC-AUC for advanced stages was 0.913 for 
cyto-c, 0.677 for CEA, 0.792 for CA19-9, and 0.507 for LD.  
Next, for patients with CRC, as shown in Table 4, the test performance characteristics 




This study presents for the first time the possibility of the use of serum cyto-c as a 
surrogate marker alternative to pathological assessment in patients with operable 
malignant tumors.  The present study clarified that cyto-c levels at the preoperative 
stage vary widely regardless of the different subtypes of cancer and stratification by 
serum cyto-c level can predict advanced status. Using uni- and multivariable analyses, 
this study also found that the elevation of serum cyto-c was closely associated with 
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serum LD activity and the presence of invasion and metastasis equivalent to the 
advanced status classified according to the TNM classification. Preoperative serum 
cyto-c levels were highly predictable for invasion and metastasis in patients diagnosed 
as having operable cancers. The test performance of cyto-c by ROC-AUC analysis was 
superior to those of the current tumor makers, LD, CEA, and CA19-9.  
Increased serum cyto-c has already been reported by in vivo and in vitro studies in 
hematological malignancies (Barczyk et al. 2005) and benign disorders involving 
systemic cell death (Hosoya et al. 2005). However, little is known about serum cyto-c 
associated with malignant solid tumors. The present findings are noteworthy to 
understand the origin of serum cyto-c in solid tumors and its usefulness as a tumor 
marker in patients with operable tumors. In addition, a strong association was evident 
between serum cyto-c and serum LD as well as the presence of invasion and distant 
metastasis. First of all, in terms of the origin of serum cyto-c, a previous study (Osaka et 
al. 2008) showed that hematological cell lines undergoing apoptosis by TRAIL can 
release cyto-c and LD into the culture medium, suggesting that both cyto-c and LD are 
mainly derived from dying tumor cells, and LD is employed as a universal death marker. 
Actually, on the origin of serum cyto-c, recent studies provide a significant suggestion of 
a close relationship between apoptosis and tumorigenesis and especially concerning   
the grade of malignancy of individual tumors common to any subtype of cancer. For 
example, the growth of malignant tumors was shown to be under an imbalanced 
homeostasis of cell proliferation and cell death by apoptosis/necrosis (Harris 2002). 
Manjo et al. (1995) reported that cells in the center of solid tumors mainly die via 
necrosis and cells at the margins are preferentially eliminated by apoptosis. Such cell 
death was documented to be spontaneous apoptosis by TUNEL methods and to have a 
role in the development and progression of cancer. Such spontaneous apoptosis is also 
reported to be involved in mitochondrial cyto-c release and the activation of caspase-3 
(Meggiato et al. 2000). Thus, it was concluded that higher levels of apoptosis reflect 
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higher grade of malignancy, which results in elevated serum cyto-c and becomes a 
negative prognostic index. Referring to these current concepts, the present results 
appear to be reasonable and valuable. Firstly, the elevation is demonstrable in only 
one-third of patients in any subtype of cancer, indicating that the elevation is not a 
common feature in cancers and results from individual cancer behavior, such as 
malignancy. On the other hand, serum cyto-c levels were independent of the size of the 
primary tumor and lymph node metastasis but dependent upon invasion and distant 
metastasis. This may represent only one facet of malignancy, such as a tumor type 
predisposed to metastasis being characterized by high apoptosis and high density of 
micro-vascularity (Tanaka et al. 2003).  Secondly, the elevation of 40ng/ml or more at 
the preoperative time predicted poor prognosis, and the elevation of cyto-c levels was 
closely associated with invasion and metastasis. All of these findings support the close 
association of cyto-c with the biological property of high grade malignancy in tumors. 
The diagnostic sensitivity of cyto-c for the presence of cancers was low, 55.6%, so 
that it is unlikely to be recommended for screening of cancers. However, for 
preoperative patients who have a cancer, the ROC-AUCs of cyto-c for invasion and 
metastasis were superior, 0.802 to 0.781, compared to those of LD, CA19-9, and CEA. 
The diagnostic sensitivities of cyto-c for invasion and metastasis in patients with 
operable tumor were 81.6% and 86.5%, respectively. These values are probably 
tolerable for the clinical setting as a new tumor marker. To our knowledge, this is the 
first report that cyto-c can predict malignant behavior.  
This unique feature of cyto-c as a tumor marker was confirmed in patients with 
gastric cancer and CRC.  Of not, the cyto-c levels were associated with the advanced 
stage classified by the presence or absence of distant metastasis and progression 
according to the TNM classification system. In particular, the ROC-AUC of cyto-c for 
metastasis in gastric cancer was high, 0.913. On the other hand, in patients with CRC, 
the test performance characteristics of cyto-c as a tumor marker were equivalent to 
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both CEA and LD but higher than CA19-9.  
The present study demonstrated that cyto-c is useful as a biomarker for pathological 
assessment involved in invasion and metastasis in patients with operable cancers. 
However, it must be repeated that cyto-c is useful as a tumor marker only in patients 
bearing cancer because serum cyto-c is also elevated in patients with non-malignant 
diseases, such as hepatitis, myocardial infarction (Alleyne et al. 2001), systemic 
inflammatory response syndrome (Adachi et al. 2004), and influenza-associated 
encephalopathy ( Hosoya et al. 2006). Accordingly, to further validate the usefulness of 
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Serum specimens from 257 patients were evaluated for cyto-c levels. Box and whisker 
plots of median (horizontal line) and 5%, 25%, 75%, and 95% percentiles of serum 
cyto-c levels in malignant and benign tumors, a: (number) Lung cancer, b: Gastric 
cancer, c: Colorectal cancer, d: Hepatobilliary and pancreatic cancer, e: Breast cancer, 
f: Ovaro-uterine cancer, g:uro-genital cancer, h: Skin cancer, i: Other malignant tumor, 
j: Benign tumor. The medians of malignant tumors and benign tumors were 20.6 ng/mL 
and 15.5 ng/mL (P = 0.020, Mann-Whitney U test). There were no significant 
differences in malignant tumor types (P = 0.362, Kruskal-Wallis H test).  
 
Figure 2 
Kaplan-Meier overall survival curves based on serum cytochrome c level in 232 
patients with malignant tumors (** p < 0.0001, * P = 0.001; Wilcoxon’s test). The Hazard 
ratio was 16.76 (95% Confidence interval 4.45-63.04; P < 0.0001 (Serum cyto-c (≧ 40 
versus < 40 ng/mL)).  
 - 13 - 
 
Figure 3 
Receiver operating characteristics (ROC) curves for the prediction of metastasis and 
invasion in patients with malignant diseases. Area under the ROC curves (AUCs) 









(mean) M:F LN M I
cytochrome c in serum
Median Range
Lung cancer 40 67.0 24:16 7 6 5 20.3 10.4-161.4 
Gastric cancer 32 62.4 18:14 8 5 3 22.6 10.7-629.3
Colorectal cancer 43 69.1 27:16 8 9 9 20.7 7.2-135.0
Hepatobilliary and pancreatic 25 65.0 17:8 3 10 5 22.8 12.3-116.0
cancer
Breast cancer 10 60.9 0:10 3 0 2 17.9 11.3-36.4
Ovaro-uterine cancer 23 57.2 0:23 1 7 5 22.3 11.0-189.5
Uro-genital cancer 27 63.5 22:5 0 4 2 20.7 11.5-179.6
Skin cancer 17 70.9 5:12 4 4 0 18.7 7.2-51.6
Other 15 63.1 9:6 6 3 6 17.4 10.8-220.4
Benign tumor 25 65.1 9:16 0 0 0 15.5 7.2-2107.6
LN L h d t t i M Oth t t i (i t li l di t t d di i t d); ymp  no e me as as s, ; er me as as s n racana cu ar , s an   an  ssem na e , 
I; Invasion  (extra organ  extension)
Invasion was not available in 30 patients. Lymph node status was not available in17 patients. 
Distant metastasis was not available in 17 patients.
Table 2. Association of preoperative serum cytochrome c levels with clinical and pathological feautures of 232 
patients with malignant diseases
No (%)
Median serum 




Age (mean) > 65 123 (53 0) 19 2 (12 3 42 3) 0 3955 0 6375 . . . - . . .
≤ 65 109 (47.0) 22.7 (13.7-66.3)
Gender M 122 (47.4) 22.6 (12.3-52.7) 0.2031 0.5843
F 110 (52 6) 19 3 (13 2-42 7). . . .
Invasion¶ Positive 37 (15.9) 29.3 (19.9-52.0) < 0.0001* 0.0004*
Negative 165 (71.1) 18.7 (12.3-36.0)
Metastatic lymph node† Positive 40 (17 2) 19 7 (11 2-29 8) 0 5745 0 3080  . . . . . .
Negative 175 (75.4) 20.7 (13.1-51.1)
Metastasis‡ Positive 48 (20.7) 31.4 (16.6-72.1) < 0.0001* 0.0262*
Negative 167 (72.0) 18.8 (12.2-33.1)
LD (median) § > 170 117 (50.0) 24.3 (13.1-47.2) < 0.0001* < 0.0001*
≤ 170 114 (49.1) 18.8 (12.0-31.5)
Total (%) 232 (100) 20.6 (12.6-50.3)
* Statistically significant.
¶ Invasion was not available in 30 patients      .
† Lymph node status was not available in 17 patients.
‡ Metastasis was not available in 17 patients.
§LD was not available in 1 patient
Table 3. Serum cytochrome c in gastric cancer
N Cytochrome c (ng/mL) CEA (ng/mL) CA19-9 (U/mL) LD (IU/L)
Median P Median P Median P Median P
Gender 0.095 0.487 0.515 0.324
M 16 26.1 3 8 152
F 15 19.1 1.6 10 170
Age 0.144 0.307 0.093 0.345
≧70 9 19.1 1.5 13 161
<70 22 23.9 2.5 8 162
Stage <0.001* 0.173 0.296 0.385
Ⅰ-Ⅱ 21 18.8 1.6 8.5 154
Ⅲ-Ⅳ 10 35.0 3.4 14 181
Lymph metastasis 0.274 0.097 0.183 0.626
N0 19 19 1 1 3 8 151. .
N1 11 25.6 2.8 12 165
Distance metastasis 0.009* 0.257 0.063 0.902
M0 25 19.1 1.6 8.5 162
M1 6 40.6 3.4 33 159
Progression 0.031* 0.337 0.878 0.256
T1, T2 24 19.1 1.6 9.5 158
T3, T4 5 29.3 3.6 8 125
* Statistically significant  .
N Cytochrome c (ng/mL) CEA (ng/mL) CA19-9 (U/mL) LD (IU/L)
Table 4. Serum cytochrome c  in  colorectal cancer
Median P Median P Median P Median P
Gender 0.757 0.825 0.152 0.052
M 27 20.7 3.2 11.5 158
F 17 24.8 2.7 14 183
Age 0.027* 0.617 0.375 0.669
≧70 22 19.1 3.1 13 172
<70 22 26.8 3 11.5 167
Stage 0.008* 0.002* 0.200 0.011*
０-Ⅱ 25 18.8 2.7 11 158
Ⅲ- 19 30.6 13.6 13 197
Distance metastasis 0.005* 0.009* 0.596 0.003*
M0 26 18.4 2.7 10.5 155
M1 18 29.7 10.3 11 216
Lymph metastasis 0.120 0.050* 0.493 0.117
N0 30 19 2 11 16.5 .7 5
N1 12 26.9 6.7 11 194
Progression 0.022* 0.004** 0.289 0.021*
T1, T2 22 18.6 2.6 9.0 155












































Cyto-c < 40 ng/mL, n = 197
C t 40 100 / L 24
0
0.1
. y o-c -  ng m , n = 
Cyto-c > 100 ng/mL, n = 11
** p < 0.0001, * P = 0.001






























Area under curves (95% CI)
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Cytochromeｃ 0.781 (0.711-0.852) 0.802 (0.730-0.873)
LD 0.651 (0.563-0.740) 0.738 (0.654-0.822)
CEA 0.676 (0.550-0.802) 0.660 (0.528-0.793)
CA19-9 0.671 (0.508-0.834) 0.710 (0.532-0.888)
